CLAIMS

[Claim 1]

Use of (+)-4-[[2-[6-fluoro-3-(4-fluorobenzyl)-3,4-dihydroisoquinolin-2(1H)-yl]ethylamino]methyl]-N-isopropylaniline monofumarate or (+)-N-[3-(methanesulfonylamino)benzyl]-2-[6-fluoro-3-(4-fluorobenzyl)-3,4-dihydroisoquinolin-2(1H)-yl]ethanamine monocitrate in the manufacture of a non-cellular root canal filler for dental tissue regeneration in an individual.

[Claim 2]

The use according to claim 1, wherein the non-cellular root canal filler further comprises extracellular matrix.

[Claim 3]

The use according to any one of claims 1 or 2, wherein the non-cellular root canal filler further comprises an anti-CCL11 neutralizing antibody and/or an ALK5 inhibitor.

[Claim 4]

The use according to any one of claims 1 to 3, wherein the non-cellular root canal filler further comprises at least one chemotactic factor selected from the group consisting of G-CSF, bFGF and SDF-1.

[Claim 5]

The use according to any one of claims 1 to 4, wherein the individual is a human 1 year of age or older and 29 years of age or younger, a rat at 1 week or more and 29 weeks or less after birth, or a dog at 1 week or more and 1 year or less after birth.

[Claim 6]

Use of a pretreatment agent comprising a serine protease; and

a non-cellular root canal filler comprising (+)-4-[[2-[6-fluoro-3-(4-fluorobenzyl)-3,4-dihydroisoquinolin-2(1H)-yl]ethylamino]methyl]-N-isopropylaniline monofumarate or (+)-

N-[3-(methanesulfonylamino)benzyl]-2-[6-fluoro-3-(4-fluorobenzyl)-3,4-dihydroisoquinolin-2(1H)-yl]ethanamine monocitrate in the manufacture of a non-cellular dental tissue regeneration promotion kit for dental tissue regeneration in an individual.

[Claim 7]

The use according to claim 6, wherein the non-cellular root canal filler further comprises extracellular matrix.

[Claim 8]

The use according to claim 6 or 7, wherein the non-cellular root canal filler further comprises an anti-CCL11 neutralizing antibody and/or an ALK5 inhibitor.

[Claim 9]

The use according to any one of claims 6 to 8, wherein the non-cellular root canal filler further comprises at least one chemotactic factor selected from the group consisting of G-CSF, bFGF and SDF-1.

[Claim 10]

The use according to any one of claims 6 to 9, wherein the serine protease is a chymotrypsin-like serine protease.

[Claim 11]

The use according to any one of claims 6 to 10, wherein the chymotrypsin-like serine protease is trypsin.

[Claim 12]

The use according to any one of claims 6 to 11, wherein the individual is a middle-aged and/or an elderly individual.